Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Protocol ID
Ponatinib-1501 /AALL1922
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
Relapse/ refractory
Location
VIC
Sponsor
Takeda
Trial Status
Open
Sites
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Year to 21 Years
International registry ID's
NCT04501614
Back to Registry
Study Title A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation
Protocol ID Ponatinib-1501 /AALL1922
Disease (Sub Disease) Leukaemia (ALL)
Diagnosis Stage Relapse/ refractory
Location VIC
Sponsor Takeda
Links https://clinicaltrials.gov/ct2/show/NCT04501614
Trial Status Open
Trial Open Date 21/02/2021
Sites Royal Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 1 Year to 21 Years
International registry ID's NCT04501614